ライフサイエンスコーパス: steroid therapy

1 hs' follow-up has led to continuation of the steroid therapy.

2 ively) after adjusting for race, income, and steroid therapy.

3 A majority of patients with DBA respond to steroid therapy.

4 d both rapidly responded to reinstitution of steroid therapy.

5 llow-up of >4 months are no longer receiving steroid therapy.

6 are candidates for rapid tapers of systemic steroid therapy.

7 d showed no overall change over 12 months of steroid therapy.

8 Patients with CoNV unresponsive to topical steroid therapy.

9 y occlusion) or receiving post-I/R high-dose steroid therapy.

10 tients (23%) had previous failure to topical steroid therapy.

11 herapy for hepatitis C, and who responded to steroid therapy.

12 ection, or hypopyon, and responds to topical steroid therapy.

13 dosterone system antagonists with or without steroid therapy.

14 t was subsequently successfully treated with steroid therapy.

15 n diagnosis was higher in patients receiving steroid therapy.

16 nd none of the patients with cancer received steroid therapy.

17 antibiotic therapy, and 1 received systemic steroid therapy.

18 adjustment for the propensity for receiving steroid therapy.

19 ival, and if this effect is synergistic with steroid therapy.

20 ancreatic organ involvement, and response to steroid therapy.

21 ymptoms have been managed with intratympanic steroid therapy.

22 -related disease or to disease relapse after steroid therapy.

23 mmunosuppression and can include maintenance steroid therapy.

24 , and consideration for drotrecogin alfa and steroid therapy.

25 with minimal change disease and response to steroid therapy.

26 es and Hazleman criteria and had not started steroid therapy.

27 eet our definition of a complete response to steroid therapy.

28 All recipients remain free of maintenance steroid therapy.

29 is self-limited and resolves with prolonged steroid therapy.

30 mune pancreatitis and to monitor response to steroid therapy.

31 is defined by primary resistance to standard steroid therapy.

32 th the start of the first course of standard steroid therapy.

33 des in this group, and none of them required steroid therapy.

34 A and that they change in patients receiving steroid therapy.

35 om one patient whose rash did not respond to steroid therapy.

36 and resolution again with re-institution of steroid therapy.

37 ation of these cells either due to asthma or steroid therapies.

38 d longer telomere length was associated with steroid therapy (0.29 +/- 0.14; P = 0.046).

39 ly developed nephrotic syndrome resistant to steroid therapy 1 week after orthopedic surgery.

40 With topical steroid therapy 5 times per day during the first postope

41 HR PK, when the VEGFR1_MO was combined with steroid therapy, a significant increase in graft surviva

42 en the Flt23k nanoparticle was combined with steroid therapy, a significant increase in graft surviva

43 influence the response to antimicrobial and steroid therapies and the risk of lung infection.

44 t trends toward improved freedom from pulsed-steroid therapy and biopsy-confirmed rejection over grou

45 Pediatric SAFS was associated with more oral steroid therapy and higher IL-33 levels.

46 treated effectively with aggressive topical steroid therapy and lubrication.

47 Two patients required steroid therapy and one required rabbit antithymocyte gl

48 function did not differ between those on QOD steroid therapy and those on QD therapy.

49 y to clarify which patients may benefit from steroid therapy and to examine long-term effects of ster

50 pulations of patients are often resistant to steroid therapy, and determining the molecular mechanism

51 s fail to satisfactorily respond to standard steroid therapy, and this type of steroid-resistant, sev

52 induced immune arthritis and its response to steroid therapy before joint destruction.

53 Early intensified postoperative topical steroid therapy constitutes an effective prophylactic tr

54 hose patients who did not respond to initial steroid therapy demonstrated a worse long-term survival

55 ation in the pancreatic LN, although topical steroid therapy did not enhance this.

56 Seven of 63 patients (11%) receiving steroid therapy died compared with 10 of 23 (43%) not re

57 ternative use of immunosuppressive agents to steroid therapy, disease remission in refractory neuro-o

58 undergone hepatoportoenterostomy, high-dose steroid therapy following surgery did not result in stat

59 nts received even empiric bolus or high-dose steroid therapy for a presumed rejection episode.

60 Among allo-HSCT patients receiving steroid therapy for acGVHD, lymphocyte binding to dermal

61 the potentially detrimental consequences of steroid therapy for anthrax must be considered in treatm

62 HIV (n=1), concomitant CGD and DM (n=1), and steroid therapy for nephrotic syndrome (n=1).

63 Patients undergoing chronic steroid therapy for organ transplantation are at increas

64 The patient was discharged and given steroid therapy for presumed IgG4-related disease.

65 old man who developed the infection while on steroid therapy for rheumatoid arthritis.

66 roles of surgical decompression and systemic steroid therapy for TON, these interventions have not be

67 organisms were previous surgery, malignancy, steroid therapy, foreign body, and immunodeficiency.

68 tropic/vasopressor therapy (1C); stress-dose steroid therapy given only in septic shock after blood p

69 Antenatal steroid therapy had a borderline-significant protective

70 Individuals receiving steroid therapy had significantly higher levels of Asper

71 chieving only moderate success with systemic steroid therapy, he was ultimately treated with recombin

72 ancreatic organ involvement, and response to steroid therapy improve the diagnostic yield for AIP.

73 for corticosteroid function in vivo and for steroid therapies in various clinical settings.

74 teroids in 123 patients (93.2%), intravenous steroid therapy in 35 patients (26.5%), cyclosporine in

75 ease-modifying antirheumatic drug (DMARD) or steroid therapy in 8 of the patients originally treated

76 ophageal ulceration ultimately responsive to steroid therapy in a 31-year old immunosuppressed, human

77 rhea associated with combined antibiotic and steroid therapy in critically ill patients not fitting i

78 Chronic steroid therapy in kidney transplantation has myriad sid

79 mechanism but also help us to better manage steroid therapy in liver diseases.

80 ulties in obtaining clinical remission under steroid therapy in some patients, resulting in long dura

81 Chronic steroid therapy in spite of myriad side effects is widel

82 a novel mechanism explaining the benefit of steroid therapy in these patients.

83 Clinical outcome of steroid therapy in this patient cohort correlated with i

84 d common bile duct strictures resolved after steroid therapy in three patients.

85 ients; use of genetic techniques and topical steroid therapy in treating graft-versus-host disease; a

86 on of zafirlukast therapy in three patients, steroid therapy in two patients, and orthotopic liver tr

87 ve surgical procedures such as intratympanic steroid therapy, intratympanic gentamicin therapy, and e

88 In patients with DMD, steroid therapy is associated with a substantial reducti

89 Steroid therapy is associated with an increased risk of

90 Steroid therapy is the current mainstay of treatment of

91 9%, respectively, for patients not receiving steroid therapy (log-rank p = 0.0005).

92 lantation is not impaired, and postoperative steroid therapy may prevent EM.

93 , if patients do not adequately benefit from steroid therapy, mortality is high and standardized trea

94 With hourly topical steroid therapy none of the patients developed CME subse

95 Steroid therapy normalized liver enzyme levels in 61%; b

96 This study sought to determine the impact of steroid therapy on cardiomyopathy and mortality in patie

97 The effect of steroid therapy on IL-33 levels in patients with neonata

98 ty of warm AIHA patients received first-line steroid therapy only, whereas patients with mixed and at

99 ose with clear indications such as long-term steroid therapy or vertebral fractures on radiography, d

100 d compared with 10 of 23 (43%) not receiving steroid therapy (p = 0.0010).

101 either long-term dietary control or chronic steroid therapies, rather than the acid-suppressive medi

102 solution of neurologic symptoms with initial steroid therapy, relapse after withdrawal of steroids, a

103 Permanent coronary occlusion or high-dose steroid therapy significantly reduced myocardial water c

104 vere asthmatic children exposed to high dose steroid therapy, therefore bronchoscopy with BAL should

105 Short-term pulse steroid therapy to treat acute rejection was necessary f

106 eturned to normal after treatment with pulse steroid therapy to treat the rejection episode.

107 ons responded to combined antitubercular and steroid therapy, usually spared fovea, and had a good fi

108 78.6%, respectively, for patients receiving steroid therapy versus 100%, 72.1%, and 27.9%, respectiv

109 steroid resistant UC patients on concomitant steroid therapies was used.

110 e of biopsy-proven acute rejection requiring steroid therapy was 6.7% in both groups.

111 Chronic steroid therapy was able to deplete the T cell products

112 Pulse steroid therapy was associated with rapid improvement of

113 Incomplete response to steroid therapy was more frequent in C4d-diffuse/focal c

114 Steroid therapy was most effective in the resolution of

115 eated attained remission and the response to steroid therapy was similar among the groups (classic sc

116 is in groups treated with both VEGFR1_MO and steroid therapy were also analyzed in HR PK.

117 a group treated with both nanoparticles and steroid therapy were also analyzed.

118 r decreased antibodies after bortezomib plus steroid therapy were identified.

119 Response rates of Banff grades I and II to steroid therapy were not different, but only 42% of grad

120 Early steroid therapy withdrawal in standard-risk patients aft